Thomas Harbo, MD, PhD, Department of Neurology, Aarhus University Hospital, Noerrebrogade 44, 8000 Aarhus C, Denmark (tel.: +45 40820643; fax: +45 89493300; e-mail: [email protected]).

This work has been carried out at the Department of Neurology, Aarhus University Hospital, Noerrebrogade 44, 8000 Aarhus C, Denmark.

Read the full text

About

PDF

Tools

Share a link

Email
Wechat
Bluesky

Abstract

Background and purpose: For treatment of multifocal motor neuropathy (MMN), we hypothesized that (i) infusion of equivalent dosages of subcutaneous immunoglobulin (SCIG) is as effective as intravenous immunoglobulin (IVIG) and that (ii) subcutaneous infusion at home is associated with a better quality of life.

Methods: In a randomized single-blinded cross-over study, nine IVIG responsive patients were allocated to receive either SCIG or IVIG for a period equivalent to three IVIG treatment intervals and, subsequently, crossed over to the other treatment. Primary end-points were (i) dynamometric strength of affected muscles and (ii) the SF-36 quality of life questionnaire.

Results: The two treatments were equally effective, the mean change in muscle strength after SCIG being 3.6% (95% CI −3.6% to 10.9%) vs. 4.3% (−1.3% to 10.0%) after IVIG (P = 0.86). One patient had sustained erythema and oedema at the injection sites for a few weeks. All other adverse effects during SCIG were mild and transient. No differences between treatments of health-related quality of life occurred.

Conclusion: In MMN, short-term subcutaneous infusion of immunoglobulin is feasible, safe and as effective as intravenous infusion. Subcutaneous administration is an alternative option that adds flexibility to the treatment schedule.

References

1 Nobile-Orazio E, Cappellari A, Priori A. Multifocal motor neuropathy: current concepts and controversies. Muscle and Nerve 2005; 31: 663–680.
10.1002/mus.20296
CAS PubMed Web of Science® Google Scholar
2 Olney RK, Lewis RA, Putnam TD, Campellone JV Jr. Consensus criteria for the diagnosis of multifocal motor neuropathy. Muscle and Nerve 2003; 27: 117–121.
10.1002/mus.10317
PubMed Web of Science® Google Scholar
3 Azulay JP, Blin O, Pouget J, et al. Intravenous immunoglobulin treatment in patients with motor neuron syndromes associated with anti-GM1 antibodies: a double-blind, placebo-controlled study. Neurology 1994; 44(3 Pt 1): 429–432.
10.1212/WNL.44.3_Part_1.429
CAS PubMed Web of Science® Google Scholar
4 Federico P, Zochodne DW, Hahn AF, Brown WF, Feasby TE. Multifocal motor neuropathy improved by IVIg: randomized, double-blind, placebo-controlled study. Neurology 2000; 55: 1256–1262.
10.1212/WNL.55.9.1256
CAS PubMed Web of Science® Google Scholar
5 Leger JM, Chassande B, Musset L, Meininger V, Bouche P, Baumann N. Intravenous immunoglobulin therapy in multifocal motor neuropathy: a double-blind, placebo-controlled study. Brain 2001; 124(Pt 1): 145–153.
10.1093/brain/124.1.145
CAS PubMed Web of Science® Google Scholar
6 Gardulf A, Hammarstrom L, Smith CI. Home treatment of hypogammaglobulinaemia with subcutaneous gammaglobulin by rapid infusion. Lancet 1991; 338: 162–166.
10.1016/0140-6736(91)90147-H
CAS PubMed Web of Science® Google Scholar
7 Chapel HM, Spickett GP, Ericson D, Engl W, Eibl MM, Bjorkander J. The comparison of the efficacy and safety of intravenous versus subcutaneous immunoglobulin replacement therapy. Journal of Clinical Immunology 2000; 20: 94–100.
10.1023/A:1006678312925
CAS PubMed Web of Science® Google Scholar
8 Van den Berg-Vos RM, Franssen H, Wokke JH, Van Es HW, Van den Berg LH. Multifocal motor neuropathy: diagnostic criteria that predict the response to immunoglobulin treatment. Annals of Neurology 2000; 48: 919–926.
10.1002/1531-8249(200012)48:6<919::AID-ANA13>3.0.CO;2-J
CAS PubMed Web of Science® Google Scholar
9 Van Schaik I, Bouche P, Illa I, et al. European Federation of Neurological Societies/Peripheral Nerve Society guideline on management of multifocal motor neuropathy. European Journal of Neurology 2006; 13: 802–808.
10.1111/j.1468-1331.2006.01466.x
CAS PubMed Web of Science® Google Scholar
10 Mathiowetz V, Kashman N, Volland G, Weber K, Dowe M, Rogers S. Grip and pinch strength: normative data for adults. Archives of Physical Medicine and Rehabilitation 1985; 66: 69–74.
CAS PubMed Web of Science® Google Scholar
11 Cutter GR, Baier ML, Rudick RA, et al. Development of a multiple sclerosis functional composite as a clinical trial outcome measure. Brain 1999; 122(Pt 5): 871–882.
10.1093/brain/122.5.871
PubMed Web of Science® Google Scholar
12 Merkies IS, Schmitz PI, Van Der Meche FG, Van Doorn PA. Comparison between impairment and disability scales in immune-mediated polyneuropathies. Muscle and Nerve 2003; 28: 93–100.
10.1002/mus.10410
PubMed Web of Science® Google Scholar
13 Bech E, Jakobsen J, Orntoft TF. ELISA-type titertray assay of IgM anti-GM1 autoantibodies. Clinical Chemistry 1994; 40(7 Pt 1): 1331–1334.
CAS PubMed Web of Science® Google Scholar
14 Tankisi H, Pugdahl K, Fuglsang-Frederiksen A, et al. Pathophysiology inferred from electrodiagnostic nerve tests and classification of polyneuropathies. Suggested guidelines. Clinical Neurophysiology 2005; 116: 1571–1580.
10.1016/j.clinph.2005.04.003
PubMed Web of Science® Google Scholar
15 Bjoerner J, Damsgaard M, Watt T, et al. Danish Manual for SF-36, Lif Lægemiddelindustriforeningen. Copenhagen, Denmark. 2007.
Web of Science® Google Scholar
16 Ware JE Jr. The status of health assessment 1994. Annual Review of Public Health 1995; 16: 327–354.
10.1146/annurev.pu.16.050195.001551
PubMed Web of Science® Google Scholar
17 Koller H, Schroeter M, Feischen H, Hartung HP, Kieseier BC. Subcutaneous self-infusions of immunoglobulins as a potential therapeutic regimen in immune-mediated neuropathies. Journal of Neurology 2006; 253: 1505–1506.
10.1007/s00415-006-0258-0
PubMed Web of Science® Google Scholar
18 Lee DH, Linker RA, Paulus W, Schneider-Gold C, Chan A, Gold R. Subcutaneous immunoglobulin infusion: a new therapeutic option in chronic inflammatory demyelinating polyneuropathy. Muscle and Nerve 2007; 37: 406–409.
10.1002/mus.20909
Web of Science® Google Scholar
19 Noreau L, Vachon J. Comparison of three methods to assess muscular strength in individuals with spinal cord injury. Spinal Cord 1998; 36: 716–723.
10.1038/sj.sc.3100646
CAS PubMed Web of Science® Google Scholar
20 Merkies IS, Lauria G. 131st ENMC international workshop: selection of outcome measures for peripheral neuropathy clinical trials 10–12 December 2004, Naarden, The Netherlands. Neuromuscular Disorders 2006; 16: 149–156.
10.1016/j.nmd.2005.12.003
CAS PubMed Google Scholar
21 Lunn MP, Leger JM, Merkies IS, Van den BP, Van SI. 151st ENMC international workshop: inflammatory Neuropathy Consortium 13th–15th April 2007, Schiphol, The Netherlands. Neuromuscular Disorders 2008; 18: 85–89.
10.1016/j.nmd.2007.08.004
CAS PubMed Google Scholar
22 Gardulf A, Nicolay U, Math D, et al. Children and adults with primary antibody deficiencies gain quality of life by subcutaneous IgG self-infusions at home. Journal of Allergy and Clinical Immunology 2004; 114: 936–942.
10.1016/j.jaci.2004.06.053
CAS PubMed Web of Science® Google Scholar
23 Nicolay U, Kiessling P, Berger M, et al. Health-related quality of life and treatment satisfaction in North American patients with primary immunedeficiency diseases receiving subcutaneous IgG self-infusions at home. Journal of Clinical Immunology 2006; 26: 65–72.
10.1007/s10875-006-8905-x
CAS PubMed Web of Science® Google Scholar
24 Hogy B, Keinecke HO, Borte M. Pharmacoeconomic evaluation of immunoglobulin treatment in patients with antibody deficiencies from the perspective of the German statutory health insurance. The European Journal of Health Economics 2005; 6: 24–29.
10.1007/s10198-004-0250-5
PubMed Google Scholar
25 Gardulf A, Andersen V, Bjorkander J, et al. Subcutaneous immunoglobulin replacement in patients with primary antibody deficiencies: safety and costs. Lancet 1995; 345: 365–369.
10.1016/S0140-6736(95)90346-1
CAS PubMed Web of Science® Google Scholar
26 Van Schaik IN, Van Den Berg LH, De Haan R, Vermeulen M. Intravenous immunoglobulin for multifocal motor neuropathy. Cochrane Database of Systematic Reviews 2005, Issue 2. Art. No.: CD004429. DOI: DOI: 10.1002/14651858.CD004429.pub2.
10.1002/14651858.CD004429.pub2
Web of Science® Google Scholar
27 Van Schaik IN, Winer JB, De Haan R, Vermeulen M. Intravenous immunoglobulin for chronic inflammatory demyelinating polyradiculoneuropathy: a systematic review. Lancet Neurology 2002; 1: 491–498.
10.1016/S1474-4422(02)00222-3
CAS PubMed Web of Science® Google Scholar
28 Dalakas MC, Illa I, Dambrosia JM, et al. A controlled trial of high-dose intravenous immune globulin infusions as treatment for dermatomyositis. New England Journal of Medicine 1993; 329: 1993–2000.
10.1056/NEJM199312303292704
CAS PubMed Web of Science® Google Scholar
29 Dalakas MC, Fujii M, Li M, Lutfi B, Kyhos J, McElroy B. High-dose intravenous immune globulin for stiff-person syndrome. New England Journal of Medicine 2001; 345: 1870–1876.
10.1056/NEJMoa01167
CAS PubMed Web of Science® Google Scholar
30 Gajdos P, Tranchant C, Clair B, et al. Treatment of myasthenia gravis exacerbation with intravenous immunoglobulin: a randomized double-blind clinical trial. Archives of Neurology 2005; 62: 1689–1693.
10.1001/archneur.62.11.1689
PubMed Web of Science® Google Scholar

Citing Literature

Volume16, Issue5

May 2009

Pages 631-638

Subcutaneous versus intravenous immunoglobulin in multifocal motor neuropathy: a randomized, single-blinded cross-over trial

Abstract

References

Citing Literature

References

Information

About Wiley Online Library

Help & Support

Opportunities

Connect with Wiley

Subcutaneous versus intravenous immunoglobulin in multifocal motor neuropathy: a randomized, single-blinded cross-over trial

Abstract

References

Citing Literature

References

Related

Information